NeuroPace, Inc.

NeuroPace, Inc. is a neurotechnology company specializing in closed-loop neuromodulation therapy for drug-resistant epilepsy. The company manufactures and markets the RNS (Responsive Neurostimulation) System, an FDA-approved implantable device designed for adults with focal epilepsy who have failed treatment with two or more anti-seizure medications. The RNS System is the only FDA-approved epilepsy device that delivers personalized, responsive treatment by detecting abnormal brain activity via EEG monitoring and delivering targeted stimulation to interrupt seizures before they occur. The system provides real-time data collection and analysis, enabling physicians to optimize individual treatment plans based on each patient's unique seizure fingerprint and triggers. The company serves epileptologists, neurosurgeons, neurologists, and comprehensive epilepsy centers across the United States. The RNS System is indicated for patients 18 years and older with localized seizure foci (no more than two) and a minimum of three seizures per month. NeuroPace provides clinical support, patient education, and healthcare provider resources including the nSight cloud-based data platform and PDMS (Patient Data Management System) for remote monitoring and device programming. The company maintains regulatory compliance with FDA approval and conducts ongoing clinical research to support therapeutic outcomes.